The UK Health Security Agency (UKHSA) offers cutting-edge capabilities to support partners tackling antimicrobial resistance (AMR). Through its Vaccine Development and Evaluation Centre (VDEC), UKHSA provides access to advanced R&D infrastructure for testing novel antimicrobials, vaccines, and diagnostics. UKHSA supports product development with high-throughput screening, genomic analysis, and regulatory-aligned evaluation. As a trusted partner, UKHSA collaborates through various initiatives and is proud to be part of the PACE programme, accelerating innovation from the lab to the clinic. Partnering with UKHSA ensures scientific excellence, credibility, and impact in the global fight against AMR.